# Baxter BioPharma Solutions to manufacture Moderna COVID-19 vaccine doses

Baxter BioPharma Solutions and Moderna have entered an agreement for Baxter to provide fill/finish sterile manufacturing services for approximately 60-90 million doses of the Moderna COVID-19 vaccine in 2021 at its Bloomington, Indiana facility.

- Type: Contract
- Announced: 2021-03-08
- Where: Bloomington, Indiana, United States
- Status: announced
- Capacity: 60-90 million doses
- Products: COVID-19 vaccine

## Companies

- [Baxter International](https://endata.com/companies/20761.md)
- [Moderna](https://endata.com/companies/47621.md) (customer)

## Sources

- [businesswire.com](https://www.businesswire.com/news/home/20210308005514/en/Baxter-BioPharma-Solutions-and-Moderna-Announce-Agreement-for-FillFinish-Manufacturing-of-the-Moderna-COVID-19-Vaccine-in-the-U.S.), 2021-03-08: "Baxter is honored to provide our deep expertise in vaccine manufacturing to help partners like Moderna bolster the supply of their vaccine."
- [biospace.com](https://www.biospace.com/baxter-biopharma-solutions-and-moderna-announce-agreement-for-fill-finish-manufacturing-of-the-moderna-covid-19-vaccine-in-the-u-s), 2021-03-08: "Baxter is honored to provide our deep expertise in vaccine manufacturing to help partners like Moderna bolster the supply of their vaccine."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.